Research use only, not for human consumption. Email [email protected]
← Research status explorer
Ignite / Metabolic

Cagrilintide

Current research status Phase 3
Active clinical development
Preclinical
Phase 1
Phase 2
Phase 3
Approved Molecule*

Overview

Cagrilintide is a long-acting amylin analogue most often studied in combination with semaglutide (as CagriSema) as well as alone. Monotherapy studies — including the registered Phase 3 REDEFINE 1 trial (NCT05567796) — have reported statistically significant weight loss versus placebo. Novo Nordisk has also described a dedicated Phase 3 program (referred to publicly as RENEW) for cagrilintide monotherapy; a specific trial record for that program name was not independently verified for this entry, so it is not cited directly.

Key research

Last reviewed: September 2026